2021 Online, In the cloud

III-47 Jurij Aguiar Zdovc
Model-based individualization of ustekinumab dosing in Crohn's disease
III-48 Orwa Albitar
A Pharmacokinetic and Pharmacodynamic Model of Cyclosporine among Malaysian Renal Transplant Patients
III-49 Muhammad Waqar Ashraf
A population pharmacokinetic model to quantify the role of in-vivo CYP2D6 activity in codeine metabolism for model informed precision dosing in ambulatory surgical patients.
III-50 Rebecca Baillie
Reuse of a published model to support compassionate use of novel drug formulation for a rare disorder
III-51 Amina Bensalem
The influence of underlying disease on rituximab pharmacokinetics may be explained by target-mediated drug disposition
III-52 Rene Boosman
The pemetrexed exposure-neutropenia relationship, paving the way to a safe administration in patients with an impaired renal function
III-53 Divakar Budda
Prediction of CNS Target Engagement of Pain reliving Drugs in Health and Chronic Pain conditions
III-54 Laura Bukkems
Population pharmacokinetics of Haemate P describing the interaction between factor VIII and Von Willebrand Factor levels in perioperative patients with von Willebrand Disease
III-55 Vera Bukkems
A combined modelling approach to assess the efficacy and safety of doravirine in pregnant women
III-56 Elisa Calvier
TMDD model to extrapolate free target reduction from competitor data in healthy volunteers to another drug in patients in order to select active dose range for phase II trials
III-57 Fernando Carreño
Modelling of Dose-Response-Time Data Using a Population k-PD approach for Linerixibat, a Locally Acting Small Molecule with Minimal Systemic Absorption
III-58 Myriam Chartoire
Development of mechanistic models for analysis and interpretation of cough challenge test data
III-59 Perrine Courlet
Model-based meta-analysis of salbutamol pharmacokinetics and practical implications for doping control
III-60 Wilbert de Witte
Continuous Time Markov Modelling in Systemic Lupus Erythematosus
III-61 Tayebeh Esmaeili
Rivaroxaban Population Pharmacokinetics Modeling in Iranian Patients
III-62 Yu Fu
A novel hemodynamic systems model to quantify pharmacodynamic effects on heart rate and contractility
III-63 Frédéric Gaspar
A step towards Ticagrelor individualization based on pharmacokinetic approaches: which place for Physiologically-Based Modelling?
III-64 Mélanie Guhl
Model-based analysis of PK equivalence: assessing the impact of model misspecification
III-65 Khalid Iqbal
A PK-PD modelling and simulation-based evaluation of tedizolid dosing strategies for immunocompromised patients
III-67 Ranita Kirubakaran
Matters close to the heart: adaptation of a tacrolimus model to inform tacrolimus therapy using the PRIOR approach
III-68 Christine Juliane Kleist
Homoarginine population kinetics
III-69 Jane Knöchel
Markov model demonstrates the importance of fibrosis distribution on clinical trial design in NAFLD/NASH
III-70 Niklas Kroemer
Development and evaluation of D-optimal 2x2 checkerboard designs for identification of pharmacodynamic drug interactions
III-71 Julia Larsson
A second-generation challenge model of TNFa turnover with LPS provocations and drug intervention
III-72 Li Li
Model-Based Approach for assessing the Effect of Anti-Drug Antibodies on the PK of Therapeutic Proteins
III-73 Qiang Lu
Semi-mechanistic Population Pharmacokinetic/Pharmacodynamic (Pop PK/PD) Modeling of Dupilumab on Nasal Congestion (NC) Score in Patients with Chronic Rhinosinusitis with Nasal Polyposis
III-74 Bastien Martin
In silico clinical trial simulation shows amelioration of ischemia-reperfusion injury in ST-elevation myocardial infarction via inhibition of reactive oxygen species production
III-75 Saikumar Matcha
Population Pharmacokinetics of Unbound Phenytoin after Administration of IV Fosphenytoin And Oral Phenytoin in Pediatric Patients.
III-76 Nicola Melillo
Development and validation of a physiologically-based pharmacokinetic model of the imaging biomarker gadoxetate for prospective prediction of hepatic transporters drug-drug interactions
III-77 Yomna Nassar
Quantifying the dynamics of the modulatory effect of CYP3A perpetrators on hepatic CYP3A activity using a nonlinear mixed-effects model of microdosed midazolam and its metabolite 1-hydroxymidazolam
III-78 Karine Elena Rodriguez
Pharmacometric characterization of entero-hepatic circulation processes of orally administered formulations of amiodarone under complex binding kinetics
III-79 Benjamin Schneider
A Quantitative Systems Pharmacology Model for Bedside Optimization of ACE Inhibitor Dose Scheduling in Veterinary Cardiology
III-80 Daniel Seeler
Towards understanding vascular (dys)regulation by linking endothelial cell morphology and blood vessel geometry
III-81 Hwang Sejung
Effect of CYP2D6 genotype on pharmacokinetics and pharmacodynamics of carvedilol for the heart rate reduction in healthy subjects
III-82 manna semere gebreyesus
Population pharmacokinetics of esomeprazole in pregnant women with preterm preeclampsia
III-83 Monica Simeoni
A Model Based Meta-Analysis for Bridging Treatment Doses of Rheumatoid Arthritis with Axial Spondyloarthritis
III-84 Leonid Stolbov
A QSP approach to investigate the glucose-insulin dynamic following dapagliflozin treatment in patients with type 2 diabetes mellitus
III-85 David Ternant
In-depth description of target-mediated pharmacokinetics of infliximab in inflammatory bowel disease patients
III-86 Wisse van Os
Targeted temperature management reduces CYP2C19 metabolism: a population pharmacokinetic study using pantoprazole
III-87 Zhigang Wang
Pharmacokinetic-Pharmacodynamic Model-Based Exploration of Alternative Ustekinumab Dosage Regimens for Patients with Crohn’s Disease
III-88 Liang Yang
A quantitative pharmacology model for CB1 receptor mediated by Gi Gs protein competition
III-89 Miren Zamacona
Population pharmacokinetic and exposure-response models for dapirolizumab pegol in patients with systemic lupus erythematosus
III-90 Chiara Zecchin
mPBPK and PD modelling and simulation to predict drug and pharmacodynamic effect at site of action and guide the design of a phase 2A/B study